If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
On May 10, 2019, the FDA approved ramucirumab as a single agent for the treatment of patients with HCC who have an AFP ≥400 ng/mL and have been treated with sorafenib therapy.1
Enclosed Prescribing Information
AFP = alpha-fetoprotein
FDA = Food and Drug Administration
HCC = hepatocellular carcinoma
Date of Last Review: March 28, 2019